Background-Patients with diabetes mellitus have reduced longevity after acute coronary syndromes and revascularization.
D iabetes mellitus is rapidly increasing globally and is expected to rise from 382 million people in 2013 to 542 million in 2035, as estimated by the International Diabetes Federation. 1 Because patients with diabetes mellitus run an articulated increased risk of cardiovascular and coronary heart disease, 2,3 this will have a major impact on future healthcare and premature death. Despite improvements in coronary care and modern evidence-based treatment, including revascularization, patients with diabetes mellitus still have a more dismal prognosis, with increased short-and long-term mortality after a coronary event compared with those without diabetes mellitus. 4 Recent reports from the Swedish Coronary Angiography Angioplasty Registry (SCAAR) demonstrated successively increasing mortality with time even after the first year after a first percutaneous coronary intervention (PCI) and especially in those treated with insulin 5 and in those with hypertension. 6 The cause of this compromised longevity has not been completely clarified. However, it is well known that patients with diabetes mellitus run an increased risk of restenosis 7 and stent thrombosis 8 and therefore also of a new cardiovascular event. The present knowledge of complication rates after revascularization is mainly derived from clinical trials and selected registries, 9 involving selected groups of patients and therefore not mirroring the actual situation seen in everyday practice. This is often true for patients with diabetes mellitus who tend to be healthier and younger when included in clinical trials. 10, 11 The nationwide SCAAR offers a unique opportunity to analyze complications from an everyday life perspective and thereby increase knowledge of morbidity patterns and reasons behind the high long-term mortality risk in patients with diabetes mellitus. The main objective in the present study was to explore complications and causes of mortality after a first PCI in unselected patients with and without diabetes mellitus in a modern setting. Diabetes, PCI, and Event Rate
Methods Patients
All consecutive patients with a first performed PCI in Sweden, included in the SCAAR between 2006 and 2010 and with no previous revascularization (coronary artery bypass grafting [CABG] or PCI) and with complete information on background characteristics and treatment, were included in the study and were followed up prospectively for events and mortality until December 31, 2010. Because of incomplete data, 347 (0.6%) were excluded from the present study. Statistical analyses were based on information collected in relation to the patient's first PCI during the study period. The SCAAR (http:// www.ucr.uu.se) collects data on every patient undergoing coronary angiography and PCI at the 29 centers that perform coronary angiography and PCI in Sweden. The data have been monitored and verified since 2001 by annually comparing 50 entered variables in 20 randomly selected interventions per hospital and year with the patient's hospital records. The overall correspondence in data during the study period was 95%. The registry is financed by the Swedish health authorities and is independent of commercial funding. The long-term follow-up was obtained by merging the SCAAR database with the Prescribed Drug Register, containing data on dispensed and collected drugs, the Swedish National Patient Register, which contains information on all inpatient care in Sweden, and the Swedish Cause of Death Registry, containing information on underlying causes of death. This is possible using the unique 10-digit personal identification number of each Swedish citizen. No patient was lost to follow-up of those still residents in Sweden.
Outcome Measures and Definitions

Diabetes Mellitus
Patients were defined as having diabetes mellitus if they had been hospitalized for diabetes mellitus at any time in the National Patient Register or were registered in the SCAAR as having diabetes mellitus or were receiving treatment with diet, oral glucose-lowering treatment, or insulin, according to the Prescribed Drug Register.
Event
The following events were collected: mortality and hospitalization for an event of acute myocardial infarction (MI), stroke, heart failure, renal failure, restenosis, and stent thrombosis in any of the coronary vessels, CABG, and new PCI. In the present study, a reported restenosis and stent thrombosis were clinically diagnosed during a cardiovascular event in need of hospitalization. A restenosis was defined as a clinically relevant stenosis of >50% or as a significant reduction in fractional flow reserve (<0.80) in a previously treated vessel segment. 12 A stent thrombosis was defined as an angiographic occlusion or visible thrombus in a previously implanted stent and was not identical to the definition given by the Academic Research Consortium. 13 Combined cardiovascular event was defined as the first occurrence of an event. Our main combined event included the first occasion of mortality, acute MI, stroke, and heart failure.
Causes of mortality were classified according to the main diagnosis on the death certificate and thereafter categorized into 8 main causes of mortality.
Statistical Analysis
Baseline characteristics, treatment, and outcome were compared in patients with and without diabetes mellitus and by diabetes mellitus treatment. Baseline characteristics are presented as the mean and SD for continuous variables and numbers and percentages for categorical variables. Only patients with complete data in the SCAAR were included in the analyses. The comparison between patients with diabetes mellitus by glucose treatment in comparison with patients without diabetes mellitus was analyzed by groups and not by pairwise comparison. The χ 2 or, when appropriate, Fisher exact test was used to compare baseline characteristics between the different groups. A Cox's proportional-hazard regression model was used to analyze the independent prediction of diabetes mellitus and different glucoselowering treatments for a future event. Twenty-nine covariates were used in the multivariate model: age, indication, sex, hospital, admission year, previous MI, previous heart failure, previous renal insufficiency, previous stroke, hypertension, hyperlipidemia, dementia, cancer diagnosis within 3 years, dialysis, chronic obstructive pulmonary disease, peripheral artery disease, smoking, angiography findings, complete revascularization, treated stenosis at bifurcation, treated chronic occlusion, bare metal stent, drug-eluting stent (DES) or balloon, numbers of stents, aspirin, clopidogrel or warfarin before PCI, glycoprotein 2B3A-inhibitor, and heparin or bivalirudin treatment during PCI. Kaplan-Meier curves were computed to illustrate time to event and absolute event rate split between patients with and without diabetes mellitus and by glucose-lowering treatment group. A 2-sided P value of <0.05 was accepted as statistically significant. All analyses were conducted using the SPSS statistical program (SPSS version 20) software from SPSS Inc, Chicago, IL.
Ethical Consideration
All patients were informed of their participation in the SCAAR. The local ethics committee at Uppsala University approved the study protocol that complies with the Declaration of Helsinki.
Results
Patients and Treatment
The baseline characteristics of the 58 891 patients are presented in Table 1 . Nineteen percent had diabetes mellitus, of whom 27% were on diet alone, 33% on oral glucose-lowering treatment, and 40% on insulin treatment. The mean age was 67 years, with a negligible yet statistically significant difference between patients with and without diabetes mellitus. In overall terms, the indication for PCI was stable coronary artery disease in 16% of the patients and an acute coronary event in 82%. On average, 70% were men, with a significantly smaller percentage in the insulin-treated diabetes mellitus group (63% men). At admission, patients with diabetes mellitus had more cardiovascular risk factors, such as hypertension, hyperlipidemia, previous MI, previous heart failure, previous stroke, renal insufficiency, and peripheral artery disease, which were more prominent in those on pharmacological glucose-lowering treatment and especially in insulin-treated patients. Coronary
WHAT IS KNOWN
• Previous studies have demonstrated different mortality rates for patients with diabetes mellitus after percutaneous coronary intervention.
WHAT THE STUDY ADDS
• Our report, based on an unselected cohort, demonstrates that diabetes mellitus is an independent predictor for adverse outcome with higher morbidity and mortality rates, including hospitalization for heart failure and myocardial infarction.
• We further demonstrate that patients with diabetes mellitus are a heterogenic group with insulin-treated diabetics having a 45% incidence of a new cardiovascular event (heart failure, myocardial infarction, and mortality) within 3 years. Diabetes, PCI, and Event Rate angiography revealed that patients on insulin more frequently had multiple-vessel disease (2 and 3 vessels or left main stem disease; 60% versus 47%) and less frequently had undergone complete revascularization (53% versus 64%) compared with those without diabetes mellitus. There was no significant difference in the numbers of stents implanted in the different groups although patients with diabetes mellitus and in particular those on insulin treatment more frequently received DESs (37% versus 24%). The use of antiplatelet and thrombin-inhibitor therapy before PCI was almost equal in the groups.
Long-Term Follow-Up
The mean follow-up period was 920 days (SD, 530 days). The estimated cumulative event and mortality rate after PCI in patients with and without diabetes mellitus and by glucose treatment are presented in Figures 1 to 5. The rates of mortality and combined cardiovascular events were highest in insulintreated patients, followed by patients on oral glucose-lowering treatment and diet treatment, whereas the lowest event rates were seen in patients without diabetes mellitus (Figures 1  and 2 ). The estimated event rate is presented in Table 2 and is derived from the Kaplan-Meier curves. After 3 years, estimated mortality rate was 22% in insulin-treated patients, 12% in those on oral treatment, 11% on those treated with diet, and 9% in those without diabetes mellitus. The corresponding figures for the combined cardiovascular event (mortality, acute MI, stroke, and heart failure) were estimated at 45%, 33%, 31%, and 25%, respectively. The unadjusted and adjusted risk of different kinds of cardiovascular events in patients with diabetes mellitus compared with those without is presented in Table 3 . The presence of diabetes mellitus in particular increased the risk of an event, such as mortality, combined cardiovascular event, heart failure, stroke, renal failure, and CABG. After adjustment, the hazard ratio (HR) for mortality was 1.91 (95% confidence interval, 1.77-2.07) in insulin-treated patients, 1 (Figure 3 ). An increased risk of stent thrombosis (present in 3% of insulin-treated patients after 3 years) and restenosis (present in 11% of insulin-treated patients after 3 years) was seen Table 4 . The most common causes of mortality were ischemic heart disease (54% versus 56%) and cancer (12% versus 18%) in patients with and without diabetes mellitus, respectively. Endocrine disease was a more common cause in patients with diabetes mellitus (11% versus 0.5%), but, apart from this, a similar pattern for causes of mortality was seen.
Discussion
The first and most important finding in this long-term follow-up analysis of a large unselected population is the high event and mortality rate after PCI in patients with diabetes mellitus, which is even present after the first occasion of revascularization. As 14 after 5 years, the corresponding figure was 27%, which probably reflects the fact that the latter trials have a healthier selected group of patients. Because bare metal stent was used to a high extent and might not mirror the situation in Sweden or United States the past years, subgroups analyses in those who only received DES were performed. This did not change the main results, and a high event rate in patients with diabetes mellitus, and in particular in those treated with insulin, was still present. Second, we found that the most common type of events after the first PCI in patients with diabetes mellitus was Table 2 The present data, with a surprisingly high risk of new events already after a first PCI in patients with diabetes mellitus and in a modern setting including the high use of stents and potent platelet-stabilizing drugs, highlight the importance of reporting and adding unselected registry data to clinical trial data, to better mirror the everyday situation. This information needs to be taken into consideration when patients and physicians decide on the choice of revascularization strategy, as well as when choosing how to monitor the follow-up period in patients with diabetes mellitus after PCI. Even though CABG may theoretically be preferred in patients with diabetes mellitus and multiple-vessel disease, according to the results of the FREEDOM trial, 14 both patients and physicians might prefer PCI on several occasions for reasons of convenience. Accordingly, our data further support the need for the careful follow-up of those patients with diabetes mellitus and especially of those on insulin treatment because the number of new events continues to grow over time. In earlier publications, secondary prevention has been shown to be pivotal in patients with diabetes mellitus. [15] [16] [17] However, our data indicate that further improved preventive strategies are needed to reduce the high risk of new cardiovascular events after PCI in patients with diabetes mellitus.
. Estimated Event Rate (%) 3 Years After First PCI in Patients With and Without Diabetes Mellitus and by Diabetes Mellitus Treatment Group
One important finding was the disproportionately higher event rate of stent thrombosis and stent restenosis among patients on insulin treatment. Even though the rate of stent thrombosis was only 3% after 3 years in those patients on 18 The most obvious reason for this finding is that insulin use represents patients with a more severe diabetes mellitus state, including more complicated coronary lesions. However, platelet dysfunction has been described as being more common in insulin-treated patients, 19 and a resistance to aspirin 20, 21 and clopidogrel 22 is more frequently present in patients with high glucose levels. Furthermore, experimental data indicate that insulin per se might accelerate the atherosclerotic process. 19 Whatever the reasons are and even though insulin per se might not be the cause of the increase in the stent thrombosis and restenosis rate, more aggressive platelet therapy seems to be advocated in those patients on insulin therapy. Subgroup analyses from the PLATelet inhibition and patient Outcomes (PLATO) trial showed that patients with HbA1c >6%, as well as those on insulin, had a reduced event rate when randomized to the more potent platelet aggregation inhibitor, ticagrelor, in comparison with clopidogrel, and with no increased risk of bleeding complications. 23 Another important question that needs to be resolved is the time frame of dual antithrombotic medication after PCI in insulin-treated individuals, where periods of therapy longer than 1 year might be needed to reduce the event rate. An important finding that might contribute to the high event rate seen in patients with diabetes mellitus is that a substantial 20% of patients on insulin treatment reported a previous hospitalization from a MI. However, these individuals had not been offered previous revascularization, an exclusion criterion in the present cohort. The underuse of revascularization in patients with diabetes mellitus has been reported in those with both heart failure 24 and acute coronary events. 5 Incomplete revascularization might contribute to the compromised longevity in patients with diabetes mellitus 5 and was indeed more common among patients with diabetes mellitus in the present cohort. However, attempting to accomplish complete revascularization might not always be possible in patients with diabetes mellitus because of the presence of diffuse extensive coronary lesions and smaller vessel lumens. Interestingly and somewhat contrary to what is usually reported, the underlying cause of mortality was shown to have a similar pattern for patients with and without diabetes mellitus. The incidence of a cardiovascular cause of mortality was ≈60% in those with diabetes mellitus, as opposed to the 70% to 80% that are usually described in many elderly recruited cohorts. 25 Therefore, there seems to have been a reduction in causes of mortality from cardiovascular disease in patients with diabetes mellitus, described as being ≈70% to 80% in those with a MI in the 1990s, to ≈60% in a modern population like that at the present time.
Strengths and Limitations
One major strength of the present report is the large size and unselected cohort, including all the patients in Sweden with a first PCI, thus mirroring an everyday life setting with a more appropriate event rate after PCI than reports from randomized clinical trials. One major limitation is the lack of reported variables related to the state of diabetes mellitus, such as type of diabetes mellitus (type 1 or type 2), duration, glycemic control, and the presence of typical small-vessel diabetes mellitusrelated complications, all of which might be more common in patients treated with insulin. It is likely that such variables, as for instance diabetes mellitus duration, explain a large part of the adverse effect related to insulin use. However, the information that a patient is treated with insulin should alert the physician of a patient at high risk. In a recent report on patients with type 2 diabetes mellitus undergoing coronary angiography, where such variables were adjusted for, the increased mortality risk related to insulin treatment was reduced but was still apparent. 26 So, it was not possible to rule out whether insulin per se affects the event rate or whether the use of insulin therapy is a risk variable confounded by indication. On the contrary, data from the recent Outcome Reduction With Initial Glargine Intervention (ORIGIN) study 27 contradict this former possibility, showing a neutral effect of insulin on cardiovascular outcome compared with standard glucose care in individuals at high cardiovascular risk and previously insulin naïve patients. However, there are major differences between the ORIGIN and the present cohort because the present article deals with patients who are not insulin naïve and all are revascularized with a first PCI. 27 Another limitation in our cohort is the lack of information on long-term treatment after the PCI, and especially on dual antiplatelet treatment. A further limitation is that the SYNTAX score describing precise information on coronary artery disease is not possible to calculate from the SCAAR angiographic report, why a more detailed extent of the disease, a part from affected coronary arteries, is not possible to adjust for in the present study.
Conclusions
The main finding in this long-term follow-up of a large unselected population with a first PCI is the high risk of a new cardiovascular event in patients with diabetes mellitus, which is even present after the first occasion of revascularization. Patients on insulin therapy run a particularly high risk of all types of event, including stent thrombosis, and they therefore need careful monitoring after PCI, including intense secondary prevention, as well as potent platelet-stabilizing drugs. 
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